CSTL News

Latest breaking news and updates for CSTL stock.

New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma

Castle announced the publication of two new studies related to its DecisionDx-SCC test for patients with high-risk cutaneous squamous cell carcinoma.

How does this development compare to competitors' offerings in the high‑risk cutaneous squamous cell carcinoma diagnostics market? What is the expected timeline for broader adoption and reimbursement coverage of the DecisionDx‑SCC test? How will the new evidence affect Castle Biosciences' revenue forecasts and valuation?

Clinical trials

5 days ago

Read more globenewswire

Castle Biosciences to Participate in Upcoming Investor Conferences

Castle Biosciences will participate in three investor conferences in September

9 days ago

Read more globenewswire

Castellum, Inc. Reports Record Quarterly Revenue, Improving Profitability, and Additional Debt Reduction with Q2 2025 Results

Castellum, Inc. Reports Record Quarterly Revenue, Improving Profitability and Additional Debt Reduction with Q2 2025 Results

What macroeconomic factors could impact CSTL's continued growth and debt reduction strategy? Are there any forward guidance updates or outlook revisions that could influence the stock’s trajectory? How might the market react to the combination of record revenue and profitability improvements in terms of volume and volatility?

22 days ago

Read more globenewswire

Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases

Castle Biosciences, Inc. today announced that it has entered entered into a collaboration and license agreement with SciBase Holding AB.

2 months ago

Read more globenewswire